Good morning and welcome to the Boston Scientific Third Quarter 2024 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an ...
The OPTION trial is a significant study for Boston Scientific as it evaluates the potential market expansion for its left-atrial-appendage-closure (LAAC) device, WATCHMAN, which is projected to ...
The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...